» 
Seasons Greetings 2022
Copy URL
https://www.pharmnovo.com/post/season-greetings-2022

Seasons Greetings 2022

December 22, 2022
Petra Larson
Author:
Petra Larson
Copy URL
https://www.pharmnovo.com/post/season-greetings-2022

Seasons Greetings 2022

December 22, 2022
Petra Larson
Author:
Petra Larson

Latest news

View all
March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Read more
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more
January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.

Read more
January 30, 2024

A new perspective in pain management and opioid withdrawal relief

We are proud to share an article in Dagens Industri about our groundbreaking work with PN6047. Our promising drug candidate not only has the potential to revolutionise pain relief but has also caught the attention of the National Institute on Drug Abuse (NIDA) for its role in opioid withdrawal treatment. Per von Mentzer, our CEO, states: "Our work with PN6047 could open new paths in pain relief. Particularly in neuropathic pain, our research could lead to new insights and novel treatment approaches in various clinical areas." PN6047, a selective DORA, offers a new perspective on both pain management and opioid withdrawal treatment. The results from the Phase I study show promising safety and tolerance, paving the way for further studies on its effects on opioid withdrawal syndrome.

Read more